These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28682832)

  • 1. New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia.
    Badar T; Luthra R; Kantarjian H; Jabbour E; Borthakur G; Garcia-Manero G; Huang X; Singh R; Alvarez B; Austermiller B; Morrison TB; Patel KP; Cortes J
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):33-39. PubMed ID: 28682832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion, correction, and International Scale standardization: results From a Multicenter External Quality Assessment Study for BCR-ABL1 testing.
    Griffiths M; Patton SJ; Grossi A; Clark J; Paz MF; Labourier E;
    Arch Pathol Lab Med; 2015 Apr; 139(4):522-9. PubMed ID: 25061833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
    Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.
    Al-Achkar W; Moassass F; Youssef N; Wafa A
    J BUON; 2016; 21(2):444-9. PubMed ID: 27273956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the challenge in measuring and standardizing BCR-ABL1.
    Yu S; Cui M; He X; Jing R; Wang H
    Clin Chem Lab Med; 2017 Aug; 55(10):1465-1473. PubMed ID: 28222016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of two commercially available BCR-ABL1 quantification assays that use an international reporting scale.
    Seo SH; Lee SJ; Park S; Kim MJ; Song JY; Ra EK; Cho SI; Kim HK; Yang MG; Kim JY; Park SS; Seong MW
    Clin Chem Lab Med; 2016 Jul; 54(7):1157-60. PubMed ID: 26587743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
    Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
    Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programme for Harmonization to the International Scale in Latin America for BCR-ABL1 quantification in CML patients: findings and recommendations.
    Ruiz MS; Sánchez MB; Vera Contreras YM; Agrielo E; Alonso M; Altuna ME; Anchordoqui MS; Asinari M; Bonetto ME; Camargo M; Giere I; González J; Granda Alacote AC; Guerra J; Gutiérrez M; Maldonado C; Makiya R; Manrique G; Monaco ME; Rozo JC; Santamaría C; Seravalle A; Zea O; Zubillaga MN; Mordoh J; Larripa I; Bianchini M
    Clin Chem Lab Med; 2020 Nov; 58(12):2025-2035. PubMed ID: 32374276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?
    Cayuela JM; Macintyre E; Darlington M; Abdelali RB; Fund X; Villarese P; Tulliez M; Raffoux E; Sigaux F; Réa D; Seror V
    Haematologica; 2011 May; 96(5):664-71. PubMed ID: 21330326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL1 transcript levels increase in peripheral blood but not in granulocytes after physical exercise in patients with chronic myeloid leukemia.
    Jönsson S; Olsson B; Jacobsson S; Palmqvist L; Ricksten A; Ekeland-Sjöberg K; Wadenvik H
    Scand J Clin Lab Invest; 2011 Feb; 71(1):7-11. PubMed ID: 20863169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry).
    Möbius S; Schenk T; Himsel D; Maier J; Franke GN; Saussele S; Pott C; Andrikovics H; Meggyesi N; Machova-Polakova K; Zizkova H; Jurcek T; Mesanovic S; Zadro R; Gottardi E; Haenig J; Schuld P; Cross NCP; Hochhaus A; Ernst T
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1645-1650. PubMed ID: 30941573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization.
    Cross NC; Hochhaus A; Müller MC
    Ann Hematol; 2015 Apr; 94 Suppl 2():S219-25. PubMed ID: 25814088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel aberrant form of e13a2 BCR-ABL1 transcript in chronic myelogenous leukemia undetectable with the standardized real-time quantitative polymerase chain reaction from the Europe Against Cancer Program.
    Matsushita H; Yamamoto M; Tsuboi K; Masukawa A; Arakawa S; Asai S; Ogawa Y; Ando K; Miyachi H
    Clin Chem Lab Med; 2009; 47(7):885-7. PubMed ID: 19575551
    [No Abstract]   [Full Text] [Related]  

  • 15. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.
    Müller MC; Erben P; Saglio G; Gottardi E; Nyvold CG; Schenk T; Ernst T; Lauber S; Kruth J; Hehlmann R; Hochhaus A;
    Leukemia; 2008 Jan; 22(1):96-102. PubMed ID: 17943168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guidelines for molecular monitoring of BCR-ABL1 in chronic myeloid leukemia patients by RT-qPCR].
    Larripa I; Ruiz MS; Gutiérrez M; Bianchini M
    Medicina (B Aires); 2017; 77(1):61-72. PubMed ID: 28140313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel approach for BCR-ABL1 standardization to improve International Scale estimation.
    Maes B; Bakkus M; Boeckx N; Boone E; Cauwelier B; Denys B; De Schouwer P; Devos T; El Housni H; Hillen F; Jacobs K; Lambert F; Louagie H; Maes MB; Meeus P; Moreau E; Nollet F; Peeters K; Saussoy P; Van Lint P; Vaerman JL; Vaeyens F; Vandepoele K; Vannuffel P; Ver Elst K; Vermeulen K; Bruyndonckx R;
    Int J Lab Hematol; 2016 Dec; 38(6):674-684. PubMed ID: 27460189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
    García-Gutiérrez V; Gómez-Casares MT; Puerta JM; Alonso-Domínguez JM; Osorio S; Hernández-Boluda JC; Collado R; Ramírez MJ; Ibáñez F; Martín ML; Rodríguez-Gambarte JD; Martínez-Laperche C; Gómez M; Fiallo DV; Redondo S; Rodríguez A; Ruiz-Nuño C; Steegmann JL; Jiménez-Velasco A;
    PLoS One; 2017; 12(3):e0173532. PubMed ID: 28278193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.
    Zhang T; Grenier S; Nwachukwu B; Wei C; Lipton JH; Kamel-Reid S;
    J Mol Diagn; 2007 Sep; 9(4):421-30. PubMed ID: 17690211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
    Link-Lenczowska D; Sacha T; Zawada M; Czekalska S; Florek I; Skotnicki AB
    Przegl Lek; 2014; 71(5):258-62. PubMed ID: 25248240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.